Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Staar Surgical Company (STAA)

Staar Surgical Company (STAA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 941,119
  • Shares Outstanding, K 49,742
  • Annual Sales, $ 313,900 K
  • Annual Income, $ -20,210 K
  • EBIT $ -97 M
  • EBITDA $ -91 M
  • 60-Month Beta 1.05
  • Price/Sales 4.06
  • Price/Cash Flow N/A
  • Price/Book 2.66

Options Overview Details

View History
  • Implied Volatility 55.96% (-21.93%)
  • Historical Volatility 48.67%
  • IV Percentile 15%
  • IV Rank 37.41%
  • IV High 135.13% on 04/16/25
  • IV Low 8.65% on 08/12/25
  • Expected Move (DTE 16) 1.79 (9.29%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 1,084
  • Volume Avg (30-Day) 582
  • Put/Call OI Ratio 1.83
  • Today's Open Interest 18,891
  • Open Int (30-Day) 18,425
  • Expected Range 17.44 to 21.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.00
  • Number of Estimates 3
  • High Estimate 0.03
  • Low Estimate -0.04
  • Prior Year -0.64
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.59 +23.32%
on 02/17/26
20.49 -6.20%
on 02/25/26
+1.68 (+9.58%)
since 02/04/26
3-Month
15.59 +23.32%
on 02/17/26
27.53 -30.19%
on 12/09/25
-7.38 (-27.74%)
since 12/04/25
52-Week
14.69 +30.84%
on 04/09/25
30.81 -37.62%
on 08/13/25
+1.47 (+8.28%)
since 03/04/25

Most Recent Stories

More News
STAAR Surgical (NASDAQ:STAA) Misses Q4 CY2025 Sales Expectations, Stock Drops 11.2%

STAAR Surgical (NASDAQ:STAA) Misses Q4 CY2025 Sales Expectations, Stock Drops 11.2%

STAA : 19.22 (+1.59%)
Staar Surgical: Q4 Earnings Snapshot

Staar Surgical: Q4 Earnings Snapshot

STAA : 19.22 (+1.59%)
STAAR Surgical Issues Shareholder Letter

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter ...

STAA : 19.22 (+1.59%)
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

Confident in China Progress and Future Roadmap A Clear Path Toward Sustainable Profitability and Growth Board and Leadership Transitions...

STAA : 19.22 (+1.59%)
STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million...

STAA : 19.22 (+1.59%)
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial...

STAA : 19.22 (+1.59%)
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

New FDA expansion of U.S. age indication extends EVO ICL use for patients 21 to 60 years old – making EVO ICL available to nearly 8 million additional refractive patients ...

STAA : 19.22 (+1.59%)
3 Low-Volatility Stocks We Find Risky

3 Low-Volatility Stocks We Find Risky

TGT : 120.08 (-0.60%)
CMCSA : 32.09 (+3.48%)
STAA : 19.22 (+1.59%)
1 Cash-Heavy Stock on Our Watchlist and 2 We Brush Off

1 Cash-Heavy Stock on Our Watchlist and 2 We Brush Off

NTAP : 99.55 (+0.77%)
AFG : 132.79 (+0.67%)
STAA : 19.22 (+1.59%)
3 Cash-Burning Stocks with Open Questions

3 Cash-Burning Stocks with Open Questions

PTLO : 5.17 (-0.77%)
STAA : 19.22 (+1.59%)
CTOS : 7.06 (+0.86%)

Business Summary

Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.

See More

Key Turning Points

3rd Resistance Point 21.80
2nd Resistance Point 20.62
1st Resistance Point 19.92
Last Price 19.22
1st Support Level 18.04
2nd Support Level 16.86
3rd Support Level 16.16

See More

52-Week High 30.81
Fibonacci 61.8% 24.65
Fibonacci 50% 22.75
Fibonacci 38.2% 20.85
Last Price 19.22
52-Week Low 14.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar